Founded in 2001., ProMab Biotechnologies develops and commercializes recombinant proteins, antibodies, and engineered cell lines through the integration of bioinformatics, molecular biology, protein expression, purification techniques, gene cloning, microbiology, and immunology, using novel high-throughput technologies. ProMab provides its proprietary proteins, engineered cell lines, and antibodies to deliver innovative research and diagnostic products, as well as services for the global biomedical research community through collaborations, partnerships, and joint ventures with other biotechnology and bio-reagent companies. ProMab has also developed a novel mRNA lipid nanoparticle (mRNA-LNP) platform for ready-to-use reagents and custom research services to advance the current offerings and expand to more fields of research. ProMab is on target to be one of the leading suppliers of bio-reagents in the twenty-first century and is committed to improving human health with a focus on the field of immunotherapy, specifically CAR-T/NK cell technologies. Since 2001, ProMab has built in-house expertise in the latest technologies to help our partners push the frontiers of medicine. Today, we are the only provider that can offer CAR-T/NK development, mRNA-LNP development, and antibody engineering-highly promising technologies on their own and even more powerful when combined. Leverage our validated platform to advance your studies into the use of LNP-based delivery of mRNAs, including the development of vaccines, engineered immune cells, or antibody-encoding mRNA solutions.
This company is:
Verified
FOXD3 Primary Antibody - 10010 - Products | ProMab
This gene belongs to the forkhead family of transcription factors which is characterized by a distinct forkhead domain. Mutations in this gene cause autoimmune susceptibility 1.
Verified
SLC7A3 - 32355 - Products | ProMab
This gene encodes a member of the solute carrier family 7. The encoded protein is a sodium-independent cationic amino acid transporter. Alternate splicing results in multiple transcripts that encoded the same protein.
Verified
Mouse Monoclonal Antibody to CDKN1A - 32024 - Products | ProMab
This gene encodes a potent cyclin-dependent kinase inhibitor. The encoded protein binds to and inhibits the activity of cyclin-cyclin-dependent kinase2 or -cyclin-dependent kinase4 complexes, and thus functions as a regulator of cell cycle progression at G1. The expression of this gene is tightly controlled by the tumor suppressor protein p53, through which this protein mediates the p53-dependent cell cycle G1 phase arrest in response to a variety of stress stimuli. This protein can interact with proliferating cell nuclear antigen, a DNA polymerase accessory factor, and plays a regulatory role in S phase DNA replication and DNA damage repair. This protein was reported to be specifically cleaved by CASP3-like caspases, which thus leads to a dramatic activation of cyclin-dependent kinase2, and may be instrumental in the execution of apoptosis following caspase activation. Mice that lack this gene have the ability to regenerate damaged or missing tissue. Multiple alternatively spliced variants have been found for this gene.
View all products
Keywords
Industries
Where is ProMab Biotechnologies Inc located?
The company ProMab Biotechnologies Inc is located in Richmond, California, United States. It's worth noting that the company may has more corporate locations
How many employees does ProMab Biotechnologies Inc approximately have?
As of the latest available information ProMab Biotechnologies Inc has around 51-100 employees worldwide.
When was ProMab Biotechnologies Inc founded?
ProMab Biotechnologies Inc was founded in 2001
In which industries does ProMab Biotechnologies Inc mainly work?
The company ProMab Biotechnologies Inc has it's main focus in the industries of Science and Engineering, Biotechnology
What is the current company status of ProMab Biotechnologies Inc?
Based on the founding year and the amount of employees the company ProMab Biotechnologies Inc seems to be a Medium-Sized Company at the current state. Note that over time that status can change
GenScript ProBio
United States
1001-5000 Employees
2002
Haematologic Technologies
United States
1987
Profacgen
United States
BioMab Inc.
Taiwan
1-10 Employees
CreativeBiomart
United States
11-50 Employees
2005
Antibody Lab GmbH
Austria
1-10 Employees
2014
ProSci Incorporated
United States
11-50 Employees
1998
GeneFrontier Japan
Japan
2010
Topics which have been searched by others and may be interesting for you:
